Raab, Marc-Steffen
German Cancer Research Center · University Hospital Heidelberg
5 papers on CoChat
Most cited papers
- Verified
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 200
- Verified
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., et al. (2015) · Haematologica
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 73
- Verified
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., et al. (2021) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 30
- Verified
Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
Heinemann, L., Möllers, K. M., Ahmed, H. M. M., Wei, L., Sun, K., Nimmagadda, S. C., Frank, D., Baumann, A., Poos, A. M., Dugas, M., et al. (2022) · Frontiers in Oncology
Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer
Cited by 15
- Verified
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free